Form 4: Alto Neuroscience Director Receives Stock Option Grant

Director Andrew Craig Miller was granted 26,000 stock options as part of the company's non-employee director compensation policy.

Summary

• Director Andrew Craig Miller received a grant of 26,000 stock options on May 27, 2026.
• The options have an exercise price of $20.44 per share.
• The options vest in 36 equal monthly installments starting June 27, 2026, contingent on continued service.
• The grant was issued under the company's standard Non-Employee Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continuous service, creating a dependency on personnel retention.

Future Outlook

The options are subject to a 36-month vesting period, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise while aligning incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of 36-month vesting schedules is consistent with standard corporate governance practices for board-level equity compensation in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Director to continue service to satisfy the 36-month vesting requirement.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Insider Trading, Stock Options, Director Compensation